International Other Current Assets vs Other Liab Analysis
IBT Stock | 704.00 4.00 0.57% |
International Biotechnology financial indicator trend analysis is infinitely more than just investigating International Biotechnology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether International Biotechnology is a good investment. Please check the relationship between International Biotechnology Other Current Assets and its Other Liab accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in International Biotechnology Trust. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Other Current Assets vs Other Liab
Other Current Assets vs Other Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of International Biotechnology Other Current Assets account and Other Liab. At this time, the significance of the direction appears to have no relationship.
The correlation between International Biotechnology's Other Current Assets and Other Liab is 0.07. Overlapping area represents the amount of variation of Other Current Assets that can explain the historical movement of Other Liab in the same time period over historical financial statements of International Biotechnology Trust, assuming nothing else is changed. The correlation between historical values of International Biotechnology's Other Current Assets and Other Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Assets of International Biotechnology Trust are associated (or correlated) with its Other Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Liab has no effect on the direction of Other Current Assets i.e., International Biotechnology's Other Current Assets and Other Liab go up and down completely randomly.
Correlation Coefficient | 0.07 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Other Current Assets
Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.Other Liab
Most indicators from International Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into International Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in International Biotechnology Trust. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. As of November 29, 2024, Selling General Administrative is expected to decline to about 1.1 M. In addition to that, Tax Provision is expected to decline to about 129.3 K
International Biotechnology fundamental ratios Correlations
Click cells to compare fundamentals
International Biotechnology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
International Biotechnology fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 302.7M | 347.8M | 326.9M | 304.9M | 308.2M | 204.7M | |
Total Stockholder Equity | 283.9M | 323.8M | 284.9M | 270.3M | 282.3M | 193.5M | |
Cash | 886K | 324K | 1.6M | 0.0 | 10.4M | 11.0M | |
Other Assets | 116K | 97K | 146K | 248K | 308.2M | 323.6M | |
Total Liab | 18.8M | 24.1M | 42.0M | 34.6M | 25.9M | 27.2M | |
Accounts Payable | 715K | 1.6M | 1.2M | 143K | 1.9M | 1.8M | |
Other Current Liab | (18.8M) | (23.5M) | (41.2M) | (32.6M) | (1.9M) | (2.0M) | |
Total Current Liabilities | 124K | 2.2M | 1.2M | 143K | 164.5K | 156.2K | |
Net Debt | 17.8M | 20.3M | 40.0M | 32.5M | (10.4M) | (9.9M) | |
Retained Earnings | 221.6M | 252.1M | 213.2M | 198.6M | (54.0M) | (51.3M) | |
Non Current Assets Total | 302.2M | 345.3M | 313.4M | 301.9M | 297.5M | 210.9M | |
Non Currrent Assets Other | (302.2M) | (345.3M) | (313.4M) | (301.9M) | (297.5M) | (312.4M) | |
Cash And Short Term Investments | 886K | 324K | 1.6M | 10.4M | 12.0M | 12.6M | |
Net Receivables | 45K | 845K | 13.3M | 2.7M | 99K | 94.1K | |
Common Stock Shares Outstanding | 38.5M | 40.5M | 41.1M | 40.6M | 38.2M | 38.0M | |
Liabilities And Stockholders Equity | 302.7M | 347.8M | 326.9M | 304.9M | 308.2M | 218.2M | |
Non Current Liabilities Total | 18.1M | 21.9M | 1.2M | 32.5M | 37.3M | 39.2M | |
Other Stockholder Equity | 229.2M | (242.2M) | (265.9M) | 61.4M | 29.9M | 23.3M | |
Total Current Assets | 369K | 2.4M | 13.3M | 2.7M | 10.6M | 11.2M | |
Other Current Assets | 163.0K | 141K | 214K | 283K | (10.5M) | (10.0M) | |
Net Tangible Assets | 239.6M | 283.9M | 323.8M | 284.9M | 327.6M | 282.9M | |
Long Term Investments | 302.2M | 345.3M | 313.4M | 301.9M | 297.5M | 302.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in International Stock
Balance Sheet is a snapshot of the financial position of International Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. International Biotechnology Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of International Biotechnology and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which International currently owns. An asset can also be divided into two categories, current and non-current.